Schrodinger Inc (SDGR) Stock Price, Quote & News

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focu...

Industry: Health Information Services

Sector: Healthcare

Phone: 212 295 5800

Website: www.schrodinger.com

Address:

1540 Broadway, 24th Floor, New York, United States

BioBuddha Mar. 11 at 1:46 PM

$SDGR taken new position

0 · Reply

Neubaufahrzeug Mar. 5 at 3:04 PM

$SDGR Added.

0 · Reply

madnessofcrowds Mar. 4 at 12:45 AM

$SDGR quadrupled my position this month. we'll see who's right in a bit.

1 · Reply

scott52 Mar. 3 at 3:52 PM

$SDGR BMO cuts price target to $24 from $32. $32 was never going to happen. And, honestly, unless they partner on their proprietary assets in 2026, there isn't a chance in hell $24 happens, either.

1 · Reply

scott52 Mar. 3 at 3:41 PM

$SDGR Ramy is speaking at TD Cowen. No wonder the stock is going down:-) Ramy gave his best Tom Carvel pitch ("Please buy our ice cream.") They will finish the dose escalation study for 3515 in q2. They reiterated their desire to partner on proprietary assets. Such a weak deal-making posture does not bode well for the upfront. But making any sort of deal that plugs the hemorrhaging cash flow statement should be well received. It's not happening anytime soon IMHO. Maybe mid-late 2027.

1 · Reply

Facade78 Mar. 3 at 3:35 PM

$SDGR shit stock btw !

0 · Reply

scott52 Feb. 28 at 3:19 AM

$SDGR Maybe Lilly will just buy them. https://blogs.nvidia.com/blog/lilly-ai-factory-live

0 · Reply

beckman07 Feb. 27 at 5:21 AM

$SDGR The problem with this company is that while the pipelines developed by its partner companies are performing quite well, when it comes to its own pipelines, there are all sorts of uncertainties—even the company itself lacks confidence. What a strange phenomenon.

2 · Reply

luckydirb Feb. 26 at 8:52 PM

$SDGR this stock will pop back to 20+ on the day when Ramy resigns. He has made a blunder to steer this usedtobe successful company into the biotech shitpool. The board should call it out and start the firing process.

0 · Reply

Weber10 Feb. 26 at 8:25 PM

$SDGR had to hold Ramys feet to the fire but he sure mentioned "AI" alot on the call yesterday hahaha... maybe he has seen finally seen the light.

1 · Reply

Schrödinger, Inc. (SDGR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 25, 2026, 8:17 PM EST - 17 days ago

Schrödinger, Inc. (SDGR) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 4:05 PM EST - 18 days ago

Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 24, 2026, 8:30 AM EST - 19 days ago

Schrödinger to Participate in Upcoming Investor Conferences

Feb 19, 2026, 6:21 AM EST - 24 days ago

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

GMAB HSTM

Feb 18, 2026, 8:30 AM EST - 25 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Feb 11, 2026, 8:30 AM EST - 4 weeks ago

Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

Jan 12, 2026, 8:30 AM EST - 2 months ago

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

Jan 9, 2026, 7:04 AM EST - 2 months ago

Schrodinger to offer Eli Lilly's AI drug discovery platform on its software

LLY

Jan 9, 2026, 7:00 AM EST - 2 months ago

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

Dec 2, 2025, 3:08 PM EST - 3 months ago

Unlocking Hidden Value In Schrodinger's Box

Nov 6, 2025, 8:30 AM EST - 4 months ago

Schrödinger to Present at Jefferies London Healthcare Conference

Nov 5, 2025, 10:41 PM EST - 4 months ago

Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 4 months ago

Schrödinger Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:30 AM EDT - 4 months ago

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Oct 22, 2025, 8:30 AM EDT - 5 months ago

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Sep 8, 2025, 3:05 PM EDT - 6 months ago

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 8:30 AM EDT - 7 months ago

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Schrödinger Announces Discontinuation of SGR-2921 Program

Aug 6, 2025, 9:20 PM EDT - 7 months ago

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Schrödinger Reports Second Quarter 2025 Financial Results

Jul 25, 2025, 8:30 AM EDT - 8 months ago

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Jul 18, 2025, 10:25 AM EDT - 8 months ago

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Jul 17, 2025, 8:00 AM EDT - 8 months ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

$Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia$

Jun 27, 2025, 8:00 AM EDT - 9 months ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 13, 2025, 1:02 PM EDT - 9 months ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Jun 12, 2025, 7:00 AM EDT - 9 months ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 6, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Jun 4, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Jun 3, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Jun 1, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 10 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 5:00 PM EDT - 10 months ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29, 2025, 8:00 AM EDT - 10 months ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 28, 2025, 12:22 PM EDT - 10 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

May 27, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 26, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 25, 2025, 10:00 AM EDT - 10 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 22, 2025, 12:00 PM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025, 8:30 AM EDT - 10 months ago

Schrödinger to Present at Jefferies Global Healthcare Conference

May 20, 2025, 11:37 PM EDT - 10 months ago

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

May 20, 2025, 6:30 AM EDT - 10 months ago

Schrödinger Announces CFO Appointment

BioBuddha Mar. 11 at 1:46 PM

$SDGR taken new position

0 · Reply

Neubaufahrzeug Mar. 5 at 3:04 PM

$SDGR Added.

0 · Reply

madnessofcrowds Mar. 4 at 12:45 AM

$SDGR quadrupled my position this month. we'll see who's right in a bit.

1 · Reply

scott52 Mar. 3 at 3:52 PM

$SDGR BMO cuts price target to $24 from $32. $32 was never going to happen. And, honestly, unless they partner on their proprietary assets in 2026, there isn't a chance in hell $24 happens, either.

1 · Reply

scott52 Mar. 3 at 3:41 PM

1 · Reply

Facade78 Mar. 3 at 3:35 PM

$SDGR shit stock btw !

0 · Reply

scott52 Feb. 28 at 3:19 AM

$SDGR Maybe Lilly will just buy them. https://blogs.nvidia.com/blog/lilly-ai-factory-live

0 · Reply

beckman07 Feb. 27 at 5:21 AM

2 · Reply

luckydirb Feb. 26 at 8:52 PM

0 · Reply

Weber10 Feb. 26 at 8:25 PM

$SDGR had to hold Ramys feet to the fire but he sure mentioned "AI" alot on the call yesterday hahaha... maybe he has seen finally seen the light.

1 · Reply

shavitmi Feb. 26 at 2:32 PM

$SDGR back to $20

0 · Reply

Laddoom Feb. 26 at 2:17 AM

$SDGR Again, this space is a growing space. Eventually, all drug discoveries will come through AI-based physics and chemistry, and the timeline is by the end of 2030.. It's true that major pharmaceutical companies are investing heavily in companies like these. While one product may have failed, this is a normal part of drug discovery. It often takes many trials before a product is finally successful.

1 · Reply

beckman07 Feb. 26 at 2:09 AM

$SDGR Does the new ACV calculation method proposed by management mean that revenue will no longer be concentrated in the fourth quarter but instead spread evenly across all four quarters? This would make performance appear to rise gradually rather than follow a peak-like trajectory?

1 · Reply

scott52 Feb. 26 at 1:06 AM

$SDGR Maybe we see a bit of a relief rally now that the world isn't coming to an end. This stock could rally to $18 and still never make it out of the shitter, which is where it belongs, frankly. Analysts all seemed underwhelmed by the call. And I can't blame them. Breakeven in 2028? They came public in 2020. LoL. Net loss of $103M in 2025. An improvement over 2024, but 2024 was an absolute dumpster fire. Well, at least they have a $240M shelf at the ready if/when Ramy fucks this up.

0 · Reply

StocktwitsEarnings Feb. 25 at 10:25 PM

$SDGR Q4 '25 Earnings Results & Recap Schrodinger Inc expects to incur significant operating losses over the next several years, though existing cash and marketable securities of $402.3M are projected to fund operations for at least 24 months.

0 · Reply

Marty030 Feb. 25 at 10:20 PM

$SDGR I'd say it was an encouraging earnings call, even though platform adoption plateaud (is that a word?) in 2025, due to 'circumstances'. Net loss 100 million (about 30% less than estimated, according to my data). Positive 2026 outlook and 400 million in cash available to make the future happen - which shows financial restraint and efficiency. Goal is profitability end of 2028, but that's of course without any promises made.

0 · Reply

Fillorkill7 Feb. 25 at 10:00 PM

$SDGR this will 10x if the rotation into biotech is sustained.

0 · Reply

Fillorkill7 Feb. 25 at 9:28 PM

$SDGR drug discovery revenue doubled?!?

1 · Reply

Luk05 Feb. 25 at 8:43 PM

$SDGR Ramy, give me that numbers...

0 · Reply

Mart7810 Feb. 25 at 3:06 PM

$SDGR it's alive!

2 · Reply

Marty030 Feb. 25 at 12:30 AM

$SDGR For the bullish case: > Newly appointed CCO/CSO in 2025 (w might already expect some results, if only via guidance) > Recent partnerships with ElyLilly and Manas AI intrisically capable of adding serious value to SDGR's platform for their customers and (thus) earnings. > 2 Phase 1 studies running (recruitment for SGR-1505 ongoing, results EO2027 ) > This is not some distrupting post-corona startup, but a 30+ year-old, stable company with deep ties to academic and corporate worlds, where people generally go for evidence-based instead of foreshadowed-possibility. > Whatever setbacks SDGR's had (because of whomever's actions), its computational platform right now looks ideally positioned for whichever future precisely because the company already has years of experience integrating AI/machine learning/LLMs with boots on the ground research & discovery. Bears have a case (SDGR has been all about foreshadowed possibillities), but with this SP I think the stock could be a steal.

1 · Reply

scott52 Feb. 24 at 4:23 PM

$SDGR I'm going to take a shot that things are not as bad as the market is making it out to be. In for another 2000 here @ $11.32.

1 · Reply

Market Cap	923.55M
Revenue (ttm)	255.87M
Net Income (ttm)	-103.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-40.36%
Debt to Equity Ratio	0.00

Volume	992,900
Avg Vol	1,421,434
Day's Range	N/A - N/A
Shares Out	73.83M
Stochastic %K	61%
Beta	1.57
Analysts	Strong Sell
Price Target	$24.20